- Home
- IRT vs NAMS Comparison
IRT vs NAMS Comparison
Compare IRT & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IRT
- NAMS
- Stock Information
- Founded
- IRT 2009
- NAMS 2019
- Country
- IRT United States
- NAMS Netherlands
- Employees
- IRT N/A
- NAMS N/A
- Industry
- IRT Real Estate Investment Trusts
- NAMS Biotechnology: Pharmaceutical Preparations
- Sector
- IRT Real Estate
- NAMS Health Care
- Exchange
- IRT Nasdaq
- NAMS Nasdaq
- Market Cap
- IRT 3.8B
- NAMS 3.1B
- IPO Year
- IRT 2013
- NAMS N/A
- Fundamental
- Price
- IRT $16.03
- NAMS $36.44
- Analyst Decision
- IRT Buy
- NAMS Strong Buy
- Analyst Count
- IRT 7
- NAMS 9
- Target Price
- IRT $22.14
- NAMS $41.89
- AVG Volume (30 Days)
- IRT 2.8M
- NAMS 1.3M
- Earning Date
- IRT 10-29-2025
- NAMS 11-05-2025
- Dividend Yield
- IRT 4.23%
- NAMS N/A
- EPS Growth
- IRT N/A
- NAMS N/A
- EPS
- IRT 0.12
- NAMS N/A
- Revenue
- IRT $645,404,000.00
- NAMS $64,006,000.00
- Revenue This Year
- IRT $4.55
- NAMS N/A
- Revenue Next Year
- IRT $4.92
- NAMS $1.67
- P/E Ratio
- IRT $133.50
- NAMS N/A
- Revenue Growth
- IRT N/A
- NAMS 762.15
- 52 Week Low
- IRT $15.87
- NAMS $14.06
- 52 Week High
- IRT $22.26
- NAMS $41.47
- Technical
- Relative Strength Index (RSI)
- IRT 35.55
- NAMS 66.19
- Support Level
- IRT $15.87
- NAMS $36.16
- Resistance Level
- IRT $16.44
- NAMS $41.47
- Average True Range (ATR)
- IRT 0.30
- NAMS 2.38
- MACD
- IRT 0.00
- NAMS 0.72
- Stochastic Oscillator
- IRT 20.39
- NAMS 64.84
About IRT Independence Realty Trust Inc.
Independence Realty Trust Inc is a real estate investment trust (REIT) that acquires, owns, operates, improves and manages multifamily apartment communities across non-gateway U.S. markets. It owns and operates multifamily apartment properties, across non-gateway U.S markets, including Louisville, Memphis, Atlanta, and Raleigh. The company is focused on gaining scale within key amenity-rich submarkets that offer school districts, retail, and various employment centers.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.